Depomed Investors Demand All-New Board

May 26, 2016

In a public letter to Depomed shareholders, investors from Starboard Value -- which holds a 9.9% stake in Depomed -- demanded that the drugmaker strip its current board.

Starboard suggested six director nominees, including Jeffrey Smith, Starboard's CEO.

“We believe the Board clearly lacks the independence,objectivity, and perspective needed to make decisions that are in the best interests of shareholders,” Starboard said in the letter.

Last May, Dublin-based rival Horizon Pharma approached Depomed with a buyout offer and after being rejected, went public with an unsolicited offer valued at $29.25 per share months later. Depomed rejected the offer, adopting a poison pill -- or shareholder rights plan -- to discourage takeover without the board's approval.

Read the letter here

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments